title: Can epidermal growth factor receptor-fluorescent in situ hybridization predict clinical benefit from cetuximab treatment in patients with non-small-cell lung cancer?
authors.forename: Toshimi
authors.initials: T
authors.lastname: Takano
authors.forename: Shuji
authors.initials: S
authors.lastname: Ota
authors.forename: Akiko
authors.initials: A
authors.lastname: Hori
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Seki
authors.forename: Kenji
authors.initials: K
authors.lastname: Eguchi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000068818:Cetuximab; D004815:Epidermal Growth Factor / Q000235:genetics*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D004815:Epidermal Growth Factor; D000068818:Cetuximab